News
An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.
The firm also said it would evaluate strategic alternatives for its animal health business and close a prostate cancer vaccine trial.
The firm said the agency cited chemistry, manufacturing, and controls issues in its complete response letter, but had no concerns about product quality.
Based on data from the BEACON and NAUTICAL studies, regulatory authorities greenlit the combo for later-line patients.
ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.
A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...
The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.
The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results